FLT3 and acute myeloid leukemia: To assess the clinical utility of FLT3-TKD monitoring in clinical practice, we retrospectively performed FLT3-TKD MRD testing using ddPCR on patients between 1 January 2017 and 1 January 2024 who had AML and FLT3-TKD mutations with at least three serial samples available.